Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 931-935

  Evoli, Amelia ^a   Padua, Luca ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Immunosuppressive therapy; MuSK; Myasthenia gravis; Rituximab; Single fiber electromyography; Thymectomy

Indexed keywords

ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MUSCLE SPECIFIC RECEPTOR TYROSINE KINASE ANTIBODY; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTRODIAGNOSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MYASTHENIA GRAVIS; PALLIATIVE THERAPY; PLASMAPHERESIS; REVIEW; THYMECTOMY; TREATMENT RESPONSE;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; THYMECTOMY;

EID: 84879161515     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.004     Document Type: Review

References (68)

1. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
2. Cavalcante P., Bernasconi P., Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 2012, 25:621-629.
3. Ströbel P., Chuang W.Y., Chuvpilo S., Zettl A., Katzenberger T., Kalbacher H., et al. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis. Role of MHC Class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 2008, 1132:143-156.
4. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884. (this issue).
5. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
6. Leite M.I., Ströbel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
7. Gomez A.M., Van Den Broeck J., Vrolix K., Janssen S.P., Lemmens M.A., Van Der Esch E., et al. Antibody effector mechanisms in myasthenia gravis-Pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43:353-370.
8. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to acetylcholine receptor, muscle-specific kinase and low-density lipoprotein-related receptor protein 4. Autoimmun Rev 2013, 12:918-923. (this issue).
9. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012, 180:798-810.
10. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386.
11. Romi F., Aarli J.A., Gilhus N.E. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 2005, 12:413-418.
12. Evoli A., Bianchi M.R., Riso R., Minicuci G.M., Batocchi A.P., Servidei S., et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008, 1132:76-83.
13. Deymeer F., Gungor-Tuncer O., Yilmaz V., Parman Y., Serdaroglu P., Ozdemir C., et al. Clinical comparison of anti-MuSK- vs antiAChR-positive and seronegative myasthenia gravis. Neurology 2007, 68:609-611.
14. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., et al. Myasthenia gravis seronegative for acetylcholine receptor antibody. Ann N Y Acad Sci 2008, 1132:84-92.
15. Oh S.J., Morgan M.B., Lu L., Hatanaka Y., Hemmi S., Young A., et al. Racial differences in myasthenia gravis in Alabama. Muscle Nerve 2009, 39:328-332.
16. Oh S.J. Muscle specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 2009, 5:53-64.
17. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14 DQ5. Neurology 2006, 66:1772-1774.
18. Bartoccioni E., Scuderi F., Augugliaro A., Chiatamone Ranieri S., Sauchelli D., Alboini P., et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009, 72:195-197.
19. Costenbader K.H., Gay S., Alarcón-Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: Which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2012, 11:604-609.
20. Hanisch E., Eger E.K., Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol 2006, 253:659-660.
21. Guptill J.F., Sanders D.B., Evoli A. Anti-MuSK antibody myasthenia gravis: clinical finding and response to therapy in two large cohorts. Muscle Nerve 2011, 44:36-40.
22. Evoli A., Tonali P.A., Padua L., LoMonaco M., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
23. Farrugia M.E., Robson M.D., Clover L., Anslow P., Newsom-Davis J., Kennett R., et al. MRI and clinical studies of facial and bulbar involvement in MuSK antibody-associated myasthenia gravis. Brain 2006, 129:1481-1492.
24. Stickler D.E., Massey J.M., Sanders D.B. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 2005, 116:2065-2068.
25. Ishii W., Matsuda M., Okamoto N., Shimojima Y., Yazaki M., Motomura M., et al. Myasthenia gravis with anti-MuSK antibody, showing progressive muscular atrophy without blepharoptosis. Intern Med 2005, 44:671-672.
26. Zouvelou V., Rentzos M., Toulas P., Evdokimidis I. MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis. J Neuroimaging 2011, 21:303-305.
27. Sanders D.B., Juel V.C. MuSK-antibody positive myasthenia gravis. Questions from the clinic. J Neuroimmunol 2008, 201-202:85-89.
28. Punga A.R., Lin S., Oliveri F., Meinen S., Rüegg M.A. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp Neurol 2011, 230:207-217.
29. Bienveniste O., Jacobson L., Farrugia M.E., Clover L., Vincent A. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J Neuroimmunol 2005, 170:41-48.
30. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12:924-930. (this issue).
31. Phillips L.H., Melnick P.A. Diagnosis of myasthenia gravis in the 1990s. Semin Neurol 1990, 10:62-69.
32. Hatanaka Y., Hemmi S., Morgan M.B., Scheufele M.L., Claussen G.C., Wolfe G.I., et al. Nonresponsiveness to anticholinesterase agents in patients with anti-MuSK-antibody-positive MG. Neurology 2005, 65:1508-1509.
33. Kawakami Y., Ito M., Hirayama M., Sahashi K., Ohkawara B., Masuda A., et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011, 77:1819-1826.
34. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12:912-917. (this issue).
35. Sanders D.B., Stälberg E.V. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve 1996, 19:1069-1083.
36. Oh S.J., Hatanaká Y., Hemmi S., Young A.M., Scheufele M.L., Nations S.P., et al. Repetitive nerve stimulation of facial muscles in MuSK antibody positive myasthenia gravis. Muscle Nerve 2006, 33:500-504.
37. Bartoccioni E., Scuderi F., Minicuci G.M., Marino M., Ciaraffa F., Evoli A. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 2006, 67:505-507.
38. Díaz-Manera J., Rojas-García R., Gallardo E., Juárez C., Martínez-Domeño A., Martínez-Ramírez S., et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nat Clin Pract Neurol 2007, 3:405-410.
39. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
40. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
41. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004, 29:484-505.
42. Barohn R.J. Treatment and clinical research in myasthenia gravis. How far have we come?. Ann N Y Acad Sci 2008, 1132:225-232.
43. Richman D.P., Agius M.A. Treatment of autoimmune myasthenia gravis. Neurology 2003, 61:1652-1661.
44. Sanders D.B., Evoli A. Immunosuppressive treatment of myasthenia gravis. Autoimmunity 2010, 43:428-435.
45. García-Carrasco M., Escárcega R.O., Fuentes-Alexandro S., Riebeling C., Cervera R. Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 2007, 6:373-378.
46. Vani J., Elluru S., Negi V.S., Lacroix-Desmazes S., Kazatchkine M.D., Bayary J., et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008, 7:440-444.
47. Lavrnic D., Losen M., Vujic A., De Baets M., Hajdukovic L.J., Stojanovic V., et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005, 76:1099-1102.
48. Punga A.R., Flink R., Askmark H., Stålberg E.V. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006, 34:111-115.
49. Zhou L., McConville J., Chaudhry V., Adams R.N., Skolasky R.L., Vincent A., et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004, 30:55-60.
50. Ohta K., Shigemoto K., Fujinami A., Maruyama N., Konishi T., Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol 2007, 14:1029-1034.
51. Kostera-Pruszczyk A., Kamińska A., Dutkiewicz M., Emeryk-Szajewska B., Strugalska-Cynowska M.H., Vincent A., et al. MuSK-positive myasthenia gravis is rare in the Polish population. Eur J Neurol 2008, 15:720-724.
52. Saulat B., Maertens P., Hamilton W.J., Bassam B.A. Anti-MuSK antibody after thymectomy in a previously seropositive myasthenic child. Neurology 2007, 69:803-804.
53. Kostera-Pruszczyk A., Kwiecinski H. Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy. J Neurol 2009, 256:1780-1781.
54. Saka E., Topcuoglu M.A., Akkaya B., Galati A., Onal M.Z., Vincent A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 65:782-783.
55. Wolfe G.I., Trivedi J.R., Oh S.J. Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis. J Clin Neuromuscul Dis 2007, 8:217-224.
56. Sanders D.B., Massey J., Juel V.C. Muscle antibody positive myasthenia gravis: response to treatment in 31 patients. Neurology 2007, 68:A299. [abstract].
57. Guptill J.T., Sanders D.B. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010, 23:530-535.
58. Pasnoor M., Wolfe G., Nations S., Trivedi J., Barohn R.J., Hervbelin L., et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010, 41:370-374.
59. Takahashi H., Kawaguchi N., Ito S., Nemoto Y., Hattori T., Kuwabara S. Is tongue atrophy reversible in anti-MuSK myasthenia gravis? Six-year observation. J Neurol Neurosurg Psychiatry 2010, 81:701-702.
60. Drachman D.B., Adams R.N., Hu R., Jones R.J., Brodsky R.A. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008, 1132:305-314.
61. Drachman D.B., Jones R.J., Brodsky R.A. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol 2003, 5:29-34.
62. Lin P.T., Martin B.A., Weinacker A.B., So Y.T. High-dose cyclophosphamide in refractory myasthenia gravis with anti-MuSK antibodies. Muscle Nerve 2006, 33:433-435.
63. Engel P., Gómez-Puerta J.A., Ramos-Casals M., Lozano F., Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011, 63:127-156.
64. Dörner T., Isenberg D., Jayne D., Wiendl H., Zillikens D., Burmester G., et al. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82-89.
65. Berrih-Aknin S., Ragheb S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B cell therapy in Myasthenia Gravis. Autoimmun Rev 2013, 12:885-893. (this issue).
66. Illa I., Dìaz-Manera J., Rojas-Garcia R., Pradas J., Rey A., Blesa R., et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2008, 201-202:90-94.
67. Maddison P., McConville J., Farrugia M.E., Davies N., Rose M., Norwood F., et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011, 82:671-673.
68. Dìaz-Manera J., Martìnez-Hernandez E., Querol L., Klooster R., Rojas-García R., Suarez-Calvet X., et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.